Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Genmab A/S today and set a price target of DKK2,000.00. The company’s shares closed last Friday at DKK2,079.33.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Sanofi, and Novartis AG. According to TipRanks, Papadakis has an average return of 4.1% and a 53.66% success rate on recommended stocks.
Genmab A/S has an analyst consensus of Moderate Buy, with a price target consensus of DKK2,035.00, a -2.13% downside from current levels. In a report released today, UBS also maintained a Buy rating on the stock with a DKK2,700.00 price target.
0MGB market cap is currently DKK129.3B and has a P/E ratio of 15.05.
Read More on GB:0MGB:
Disclaimer & DisclosureReport an Issue
- Genmab price target raised to $49 from $46 at Truist
- Genmab price target raised to $40 from $36 at H.C. Wainwright
- Genmab’s Strategic Acquisitions and Promising Pipeline Drive Buy Rating
- Genmab’s Strategic Acquisition of MRUS: A Long-Term Positive Move Enhancing Pipeline and Growth Potential
- Genmab price target raised to $34 from $32 at Leerink
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)